Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

William Telle

Urology Hot Springs, AR Medical Doctor

NPI 1942267984 CMS profile 1073461

1662 Higdon Ferry Rd., Ste 140, Hot Springs, AR 71913

Open in the dashboard

General payments

$1,374

81 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, William Telle of Hot Springs, AR is reported in the CMS Open Payments database as having received $1,374 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 37th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $233 12
2022 General $240 13
2021 General $301 18
2020 General $182 11
2019 General $419 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Telle
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to William Telle were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year William Telle Urology median Middle half National median
2019 $419 $480 $147–$1,201 $163
2020 $182 $246 $87–$645 $114
2021 $301 $358 $111–$1,000 $132
2022 $240 $476 $143–$1,263 $149
2023 $233 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Biotech, Inc. $270 13 payments
  2. Astellas Pharma US Inc $220 16 payments
  3. Pfizer Inc. $130 8 payments
  4. Boston Scientific Corporation $101 5 payments
  5. Axonics Modulation Technologies, Inc. $64 3 payments
  6. Antares Pharma, Inc. $63 5 payments
  7. Myriad Genetic Laboratories, Inc. $51 3 payments
  8. Blue Earth Diagnostics Limited $49 2 payments
  9. Coloplast Corp $48 4 payments
  10. Merck Sharp & Dohme Corporation $38 2 payments
  11. Other $341 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,346 79 payments
  2. Education $28 2 payments
Products named General payments · program years 2019–2023
  1. XTANDI $290 20 payments
  2. ERLEADA $286 14 payments
  3. MYRBETRIQ $205 15 payments
  4. VESICARE $66 5 payments
  5. PAXLOVID $64 3 payments
  6. ORGOVYX $64 3 payments
  7. Prolaris $51 3 payments
  8. Axumin $49 2 payments
  9. rezum Generator $48 2 payments
  10. Axonics $47 2 payments
  11. Other $618 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

61

Median for Urology: 1,053

Drug cost

$1,812

Median for Urology: $101,464

Branded share of claims

0%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Solifenacin Succinate Generic 13 $855
Tamsulosin Hcl Generic 31 $681
Finasteride Generic 17 $276

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record